10 reasons for choosing pantoprazole for patients on polytherapy Review article
Article Sidebar
Published:
Jun 30, 2021
Keywords:
proton pump inhibitors, pantoprazole, drugs interactions, gastroprotection, Helicobacter pylori eradication
Main Article Content
Abstract
Proton pump inhibitors are the most effective therapy for all the acid-dependent diseases. Pantoprazole has been used since 1997 and it has a precise and predictable profile of activity. Pantoprazole maintains its stability in higher gastric pH with concomittant antiacids. Its constant bioavaibility and maximal blood levels are achieved after the first dose. Pantoprazole is approved for a variety of gastric acid-related diseases: gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, functional dyspepsia, NSAID-induced gastropathy treatment and prevention, and Zollinger-Ellison syndrome. Pantoprazole has been shown to have no significant interactions with other medications: especially important with antiplatelet drugs (clopidogrel), but also antipyrine, carbamazepine, ciclosporin, clarithromycin, diclofenac, naproxen, nifedipine, oral contraceptives, tacrolimus, theophylline, warfarin, and also ethanol. Pantoprazole is the very good choice particularly in patients taking multiple concomitant medications – such as the elderly or those receiving drugs with a narrow therapeutic window. Even in the long-term therapy, pantoprazole seems to be well tolerated with no identified safety concerns.
Article Details
How to Cite
Skrzydło-Radomańska , B. (2021). 10 reasons for choosing pantoprazole for patients on polytherapy. Medycyna Faktow (J EBM), 14(2(51), 139-144. https://doi.org/10.24292/01.MF.0221.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Robinson M. Clinical Pharmacology of Proton Pump Inhibitors. Drugs. 2003; 63(24): 2739-54.
2. Cheer SM, Prakash A, Faulds D et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management in acid-related disorders. Drugs. 2003; 63: 101-33.
3. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol. 1996; 8(suppl 1): S15-S20.
4. Blume H, Donath F, Warnke A et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Saf. 2006; 29(9): 769-84.
5. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-11.
6. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007; 3(2): 231-43.
7. Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther. 1996; 10: 359-66.
8. Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016; 14(1): 179-209.
9. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16: 800-8; e807.
10. Mathews S, Reid A, Tian Ch et al. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Experiment Gastroenterol. 2010; 3: 11-6.
11. Regula J, Butruk E, Dekkers C et al. Prevention of NSAID-Associated Gastrointestinal Lesions: a Comparison Study Pantoprazole versus Omeprazole. Am J Gastroenterol. 2006; 101: 1747-55.
12. Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Critical Care. 2005; 9: 45-50.
13. Hirota K, Kudo M, Hashimoto H et al. The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy. Anesth Analg. 2005; 101: 1038-41.
14. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today. 2004; 40(suppl A): 9-14.
15. Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1): 85-92.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001; 120: 594-606.
17. Bremer S, Reinhardt L, Sobotta M et al. Pantoprazole does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients. Front Med. 2018; 5: 2-4.
18. Blume H, Donath F, Warnke A et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-84.
19. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized , placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
20. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012; 35(2): 127-39.
21. Li XO, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton-pump inhibiting drugs: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(8): 821-7.
22. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019; 157: 403-12.
23. Bacak BS, Patel M, Tweed E et al. What is the best way to manage GERD symptoms in the elderly? J Fam Pract. 2006; 55: 248-51.
24. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004; 36: 243-7.
25. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013; 347: f4587.
26. Lieber CS. Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Digestion. 1997; 58: 203-10.
27. De Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy and treatment for Helicobacter pylori infection. Lancet. 1995; 345(8953): 806-20.
28. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012; 974594.
29. Zullo A, Ridola L, Francesco VD et al. High-dose esomeprazole and amoxicilline dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Am J Gastroenterol. 2015; 28: 448-51.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28(7): 868-77.
31. Malfertheiner P, Megraud F, O’Morain CA et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
32. Pellicano R, Zagari RM, Zhang S et al. Pharmacological consideration and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018; 64: 310-21.
33. Heinze H, Fischer R, Pfutzer R et al. Lack of interaction between pantoprazole and ethanol. Clin Drug Invest. 2001; 21(5): 345-51.
34. Hartmann M, Zech K, Bliesath H et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999; 37(4): 159-64.
35. Tielemans MM, van Oijen MGH, Mulder CJJ. Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. Eur J Gastroenterol Hepatol. 2012; 24: 201-7.
36. Yeomans N, Lanas A, Labenz J et al. Efficacy of Esomeprazole (20mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. Am J Gastroenterol. 2008; 103: 2465-73.
37. Gąsiorowska A, Janiak M, Waśko-Czopnik D et al. Postępowanie u pacjentów z objawami choroby refluksowej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2019; 3-4: 245-65.
38. Dąbrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Gastroenterology Rev. 2018; 13(1): 6-15.
39. Brenner G, Athman C, Schneider A. Long-term open-label trial: safety and efficacy of continous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012; 36: 37-47.
40. Li YX, Chen FCh, Liu T et al. Pantoprazole (PPZ) inhibits RANKL-Induced osteoclast formation and function in vitro and prevents lipopolysaccharide – (LPS-)induced inflammatory calvarial bone loss in vivo. Stem Cells Int. 2020; 2020: 8829212.
2. Cheer SM, Prakash A, Faulds D et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management in acid-related disorders. Drugs. 2003; 63: 101-33.
3. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol. 1996; 8(suppl 1): S15-S20.
4. Blume H, Donath F, Warnke A et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Saf. 2006; 29(9): 769-84.
5. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-11.
6. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007; 3(2): 231-43.
7. Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther. 1996; 10: 359-66.
8. Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016; 14(1): 179-209.
9. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16: 800-8; e807.
10. Mathews S, Reid A, Tian Ch et al. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Experiment Gastroenterol. 2010; 3: 11-6.
11. Regula J, Butruk E, Dekkers C et al. Prevention of NSAID-Associated Gastrointestinal Lesions: a Comparison Study Pantoprazole versus Omeprazole. Am J Gastroenterol. 2006; 101: 1747-55.
12. Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Critical Care. 2005; 9: 45-50.
13. Hirota K, Kudo M, Hashimoto H et al. The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy. Anesth Analg. 2005; 101: 1038-41.
14. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today. 2004; 40(suppl A): 9-14.
15. Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1): 85-92.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001; 120: 594-606.
17. Bremer S, Reinhardt L, Sobotta M et al. Pantoprazole does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients. Front Med. 2018; 5: 2-4.
18. Blume H, Donath F, Warnke A et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-84.
19. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized , placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
20. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012; 35(2): 127-39.
21. Li XO, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton-pump inhibiting drugs: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(8): 821-7.
22. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019; 157: 403-12.
23. Bacak BS, Patel M, Tweed E et al. What is the best way to manage GERD symptoms in the elderly? J Fam Pract. 2006; 55: 248-51.
24. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004; 36: 243-7.
25. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013; 347: f4587.
26. Lieber CS. Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Digestion. 1997; 58: 203-10.
27. De Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy and treatment for Helicobacter pylori infection. Lancet. 1995; 345(8953): 806-20.
28. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012; 974594.
29. Zullo A, Ridola L, Francesco VD et al. High-dose esomeprazole and amoxicilline dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Am J Gastroenterol. 2015; 28: 448-51.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28(7): 868-77.
31. Malfertheiner P, Megraud F, O’Morain CA et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
32. Pellicano R, Zagari RM, Zhang S et al. Pharmacological consideration and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018; 64: 310-21.
33. Heinze H, Fischer R, Pfutzer R et al. Lack of interaction between pantoprazole and ethanol. Clin Drug Invest. 2001; 21(5): 345-51.
34. Hartmann M, Zech K, Bliesath H et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999; 37(4): 159-64.
35. Tielemans MM, van Oijen MGH, Mulder CJJ. Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. Eur J Gastroenterol Hepatol. 2012; 24: 201-7.
36. Yeomans N, Lanas A, Labenz J et al. Efficacy of Esomeprazole (20mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. Am J Gastroenterol. 2008; 103: 2465-73.
37. Gąsiorowska A, Janiak M, Waśko-Czopnik D et al. Postępowanie u pacjentów z objawami choroby refluksowej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2019; 3-4: 245-65.
38. Dąbrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Gastroenterology Rev. 2018; 13(1): 6-15.
39. Brenner G, Athman C, Schneider A. Long-term open-label trial: safety and efficacy of continous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012; 36: 37-47.
40. Li YX, Chen FCh, Liu T et al. Pantoprazole (PPZ) inhibits RANKL-Induced osteoclast formation and function in vitro and prevents lipopolysaccharide – (LPS-)induced inflammatory calvarial bone loss in vivo. Stem Cells Int. 2020; 2020: 8829212.